Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: Critical analysis of the latest data and European guidance

Scandinavian Journal of Urology and Nephrology

Volumn 46, Issue 2, 2012, Pages 108-116

  Malmström, Per Uno ^a   Grabe, Magnus ^b   Haug, Erik Skaaheim ^c   Hellström, Pekka ^d   Hermann, Gregers G ^e   Mogensen, Karin ^e   Raitanen, Mika ^f   Wahlqvist, Rolf ^g  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c VESTFOLD HOSPITAL TRUST   (Norway)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Central Hospital   (Finland)

^g AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bladder cancer; Cystoscopy; Fluorescence cystoscopy; Hexaminolevulinate; Non muscle invasive bladder cancer; Photosensitizer; Residual tumour; Transurethral resection of bladder tumour; Tumour recurrence; TURBT

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL PRACTICE; CYSTOSCOPY; DENMARK; DIAGNOSTIC VALUE; EVIDENCE BASED PRACTICE; FINLAND; FLUORESCENCE CYSTOSCOPY; HUMAN; INTERNATIONAL COOPERATION; MEDICAL EXPERT; NORWAY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SWEDEN;

AMINOLEVULINIC ACID; CONSENSUS; CYSTOSCOPY; EUROPE; FLUORESCENCE; HUMANS; PHOTOSENSITIZING AGENTS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 84858407865     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2011.633279     Document Type: Article

References (18)

1. Witjes JA, Redorta JP, Jacqmin D, Sofras F, Malmström PU, Riedl C, et al. Hexaminolevulinate-guided fluorescence cys-toscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol 2010;57:607-14.
2. Frampton JE, Plosker GL. Hexyl aminolevulinate in the detection of bladder cancer. Drugs 2006;66:571-8.
3. Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 2010;57: 595-606.
4. Jichlinski P, Jacqmin D. Photodynamic diagnosis in non-muscle-invasive bladder cancer. Eur Urol Suppl 2008;7: 529-35.
5. Schumacher MC, Holmäng S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 2010;57:293-9.
6. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
7. Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184:1907-14.
8. Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int 2011;108: E297-303.
9. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.
10. Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005;174:862-6. (Pubitemid 41140613)
11. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62-7. (Pubitemid 46908731)
12. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171:135-8. (Pubitemid 37549108)
13. Gofrit ON, Pode D, Lazar A, Katz R, Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 2006;49:303-7.
14. Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 2003;170:438-41. (Pubitemid 36870219)
15. Dindyal S, Nitkunan T, Bunce CJ. The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer. Photodiagnosis Photodyn Ther 2008;5: 153-8.
16. Malmström PU, Hedelin H, Thomas YK, Thompson GJ, Durrant H, Furniss J. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol 2009;43:192-8.
17. Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TRL, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, Immunocyst, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010;14:1-331.
18. Grimbergen MCM, van Swol CFP, Jonges TGN, Boon TA, van Moorselaar RJA. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 2003; 44:51-6. (Pubitemid 36741375)